TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NITHIODOTE

SODIUM NITRITE
Approved 2011-01-14
1
Indication
--
Phase 3 Trials
1
Priority Reviews
15
Years on Market

Details

Status
Prescription
First Approved
2011-01-14
Routes
INTRAVENOUS, INTRAVENOUS
Dosage Forms
SOLUTION, SOLUTION

Companies

Active Ingredient: SODIUM NITRITE , SODIUM THIOSULFATE

NITHIODOTE Approval History

Loading approval history...

What NITHIODOTE Treats

1 indications

NITHIODOTE is approved for 1 conditions since its original approval in 2011. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cyanide Poisoning
Source: FDA Label

NITHIODOTE Boxed Warning

LIFE THREATENING HYPOTENSION AND METHEMOGLOBIN FORMATION Sodium nitrite can cause serious adverse reactions and death in humans, even at doses less than twice the recommended therapeutic dose. Sodium nitrite causes hypotension and methemoglobin formation, which diminishes oxygen carrying capacity. Hypotension and methemoglobin formation can occur concurrently or separately. Because of these risks, sodium nitrite should be used to treat acute life-threatening cyanide poisoning and be used with ca...

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NITHIODOTE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

NITHIODOTE is indicated for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, carefully weigh the potentially life-threatening risks associated with NITHIODOTE against the potential benefits, especially if the patient is not in extremis. NITHIODOTE, an antidote, is indicated for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. Use with caution if the diagnosis of cyanide poisoning is uncertain.

โš ๏ธ BOXED WARNING

WARNING: LIFE THREATENING HYPOTENSION AND METHEMOGLOBIN FORMATION Sodium nitrite can cause serious adverse reactions and death in humans, even at doses less than twice the recommended therapeutic dose. Sodium nitrite causes hypotension and methemoglobin formation, which diminishes oxygen carrying ca...

NITHIODOTE Patents & Exclusivity

Latest Patent: Dec 2031

Patents (9 active)

US8568793 Expires Dec 24, 2031
US8496973 Expires Mar 29, 2031
US9345724 Expires Jul 7, 2030
US10479686 Expires Jul 7, 2030
US9585912 Expires Jul 7, 2030
US11753301 Expires Feb 10, 2030
US9687506 Expires Feb 10, 2030
US12304813 Expires Feb 10, 2030
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.